Phosphorothioate‑modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Cao,Fei; Ju,Xiaoping; Chen,Di; Jiang,Lingong; Zhu,Xiaofei; Qing,Shuiwang; Fang,Fang; Shen,Yuxin; Jia,Zhen; Zhang,Huojun

doi:10.3892/mmr.2017.6778

Phosphorothioate‑modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

Authors:
- Fei Cao
- Xiaoping Ju
- Di Chen
- Lingong Jiang
- Xiaofei Zhu
- Shuiwang Qing
- Fang Fang
- Yuxin Shen
- Zhen Jia
- Huojun Zhang
View Affiliations

Affiliations: Department of Radiation Oncology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: June 14, 2017 https://doi.org/10.3892/mmr.2017.6778
Pages: 2089-2094

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emergence of resistance, unavoidable systemic toxicity and unsatisfactory efficacy arethe main obstacles for traditional cancer therapy. Combination with phosphorothioate modified antisense oligonucleotides (PS‑ASODN) against human telomerase reverse transcriptase (hTERT) may enhance the therapeutic effect of irradiation. However, the effect of PS‑ASODN against hTERT on the anti‑tumor effects of irradiation in liver cancer remain unclear. In the current study, Walker 256 cells were transfected with hTERT PS‑ASODN. Cell proliferation and cell viability were measured using the MTT assay and cell senescence was examined by SA‑β‑gal staining. Telomerase activity was determined by telomeric repeat amplification protocol‑polymerase chain reaction‑ELISA. Cell apoptosis was assayed by flow cytometry and DNA damage was determined by the comet assay.The PS‑ASODN was demonstrated to have an inhibitory effect on cell proliferation and accelerated effect on cell senescence by inhibiting telomerase activity. PS‑ASODN promoted the irradiation‑induced inhibition of cell viability and telomerase activity, and irradiation‑induced DNA damage and cell apoptosis via the activation of apoptosis‑associated proteins. Taken together, these results indicated that combined treatment of PS‑ASODN with irradiation significantly enhanced tumor inhibition. Therefore, PS‑ASODN provides an experimental foundation for gene therapy and is proposed for application in clinical treatment of liver cancer combined with radiotherapy.

View Figures

View References

1	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lebedeva IV and Stein CA: Antisense oligonucleotides in cancer: Recent advances. BioDrugs. 13:195–216. 2000. View Article : Google Scholar : PubMed/NCBI
4	Walther W and Schlag PM: Current status of gene therapy for cancer. Curr Opin Oncol. 25:659–664. 2013. View Article : Google Scholar : PubMed/NCBI
5	Nittis T, Guittat L and Stewart SA: Alternative lengthening of telomeres (ALT) and chromatin: Is there a connection? Biochimie. 90:5–12. 2008. View Article : Google Scholar : PubMed/NCBI
6	Rao YK, Kao TY, Wu MF, Ko JL and Tzeng YM: Identification of small molecule inhibitors of telomerase activity through transcriptional regulation of hTERT and calcium induction pathway in human lung adenocarcinoma A549 cells. Bioorg Med Chem. 18:6987–6994. 2010. View Article : Google Scholar : PubMed/NCBI
7	Fan XK, Yan RH, Li BJ, Chen XM, Wei L and Wang Z: Antisense oligodeoxynucleotide against human telomerase reverse transcriptase inhibits the proliferation of Eca-109 esophageal carcinoma cells. Exp Ther Med. 8:1247–1252. 2014.PubMed/NCBI
8	Ponnala S, Chetty C, Veeravalli KK, Dinh DH, Klopfenstein JD and Rao JS: MMP-9 silencing regulates hTERT expression via β1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells. Cell Signal. 23:2065–2075. 2011. View Article : Google Scholar : PubMed/NCBI
9	Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG and Zaffaroni N: Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer. 41:624–634. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP and Meye A: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 9:3794–3800. 2003.PubMed/NCBI
11	Sekoguchi S, Nakajima T, Moriguchi M, Jo M, Nishikawa T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, et al: Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J Gastroenterol Hepatol. 22:182–190. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kaul Z, Cesare AJ, Huschtscha LI, Neumann AA and Reddel RR: Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. 13:52–59. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
14	Sekaran VG, Soares J and Jarstfer MB: Structures of telomerase subunits provide functional insights. Biochim Biophys Acta. 1804:1190–1201. 2010. View Article : Google Scholar : PubMed/NCBI
15	Donate LE and Blasco MA: Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci. 366:76–84. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zvereva MI, Shcherbakova DM and Dontsova OA: Telomerase: Structure, functions, and activity regulation. Biochemistry (Mosc). 75:1563–1583. 2010. View Article : Google Scholar : PubMed/NCBI
17	Agrawal A, Dang S and Gabrani R: Recent patents on anti-telomerase cancer therapy. Recent Pat Anticancer Drug Discov. 7:102–117. 2012. View Article : Google Scholar : PubMed/NCBI
18	Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR and Omidi Y: Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol. 6:360–369. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhao FJ, Zhang SL, Ma L, Gao H and Zong ZH: Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines. Eur J Gynaecol Oncol. 30:54–59. 2009.PubMed/NCBI
20	Loriot Y, Mordant P, Brown BD, Bourhis J, Soria JC and Deutsch E: Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): In vitro and in vivo enhancement of radiation response. Anticancer Res. 30:3869–3878. 2010.PubMed/NCBI
21	Zhang KZ, Xu JH, Huang XW, Wu LX, Su Y and Chen YZ: Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacol Sin. 28:105–110. 2007. View Article : Google Scholar : PubMed/NCBI
22	Yuan Y, Cai H, Yang XJ, Li W, He J, Guo TK and Chen YR: Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. Asian Pac J Cancer Prev. 15:5529–5533. 2014. View Article : Google Scholar : PubMed/NCBI
23	Svinareva LV, Glukhov AI, Moskaleva EY and Shvets VI: Effect of modified DNA and RNA oligonucleotides on telomerase activity and tumor cell survival in vitro. Appl Biochem Micro. 47:718–722. 2011. View Article : Google Scholar
24	Wang XS, Wang K, Li X and Fu SB: Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activity. World J Gastroenterol. 10:3455–3458. 2004. View Article : Google Scholar : PubMed/NCBI
25	Gao XD and Chen YR: Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells. Asian J Androl. 9:697–704. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ji XM, Xie CH, Fang MH, Zhou FX, Zhang WJ, Zhang MS and Zhou YF: Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy. Acta Pharmacol Sin. 27:1185–1191. 2006. View Article : Google Scholar : PubMed/NCBI
27	Fan XK, Yan RH, Li BJ, Chen XM, Wei L and Wang Z: Antisense oligodeoxynucleotide against human telomerase reverse transcriptase inhibits the proliferation of Eca-109 esophageal carcinoma cells. Exp Ther Med. 8:1247–1252. 2014.PubMed/NCBI